RE: In Orbit Testing25 May 2018 14:51
Rom, I doubt I could be more confused... or maybe I'm not and it's all brutally simple?
The way I read the Apr 9th RNS was simply that AVN knew it had $90m of short-term liabilities already incurred that were due to be paid out during Q3 2018. I further took it that against its own projected revenues and cash position for Q3 2018, it could see that it simply didn't have the funds to cover those already incurred liabilities... hence its statement that it needed to source an extra $50m... or $90m, if that extra $40m of "infrequently occurring revenue" (whatever that refers to) didn't drop in time.
IMV, one of those liabilities is deffo the final payment against H-4, which becomes payable as soon as successful in-orbit testing is completed. From memory, that's (coincidentally) $40m or thereabouts. The other $50m will, I suspect, be a combination of running costs, accrual of interest against the remaining bonds, servicing other debt, creditor invoices etc etc.
So I see those two $40m amounts (one definitely due out soon and one hopefully due in soon) as completely separate things.
Mind you, it's worth noting that throughout its history, AVN has danced with death on the very edge of the precipice more than once before and has always managed to pull a last-minute rabbit out of the hat. Maybe it'll manage to do so again - though that trick becomes ever increasingly harder to pull off, once it's been repeated once or twice... and this time of course we've had an "either the directors or a creditor may well put the company into liquidation" RNS, which is a new thing.
All speculation - which is completely down to the ongoing bizarre radio silence from the AVN BoD. 36 days and counting...